These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 20554645)

  • 21. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
    Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
    Qin J; Zhang Z; Liu J; Sun L; Hu L; Cooper ME; Cao Z
    Kidney Int; 2003 Aug; 64(2):565-71. PubMed ID: 12846751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.
    de Zeeuw D; Anzalone DA; Cain VA; Cressman MD; Heerspink HJ; Molitoris BA; Monyak JT; Parving HH; Remuzzi G; Sowers JR; Vidt DG
    Lancet Diabetes Endocrinol; 2015 Mar; 3(3):181-90. PubMed ID: 25660356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. eNOS/Hsp70 interaction on rosuvastatin cytoprotective effect in neonatal obstructive nephropathy.
    Manucha W; Kurbán F; Mazzei L; Benardón ME; Bocanegra V; Tosi MR; Vallés P
    Eur J Pharmacol; 2011 Jan; 650(2-3):487-95. PubMed ID: 20940012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of rosuvastatin on capillary filtration of albumin and blood pressure in rats with streptozotocin-induced diabetes.
    Tarhzaoui K; Valensi P; Boulakia FC; Lestrade R; Albertini JP; Behar A
    Diabetes Res Clin Pract; 2008 Jun; 80(3):335-43. PubMed ID: 18406000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment.
    Whaley-Connell A; Habibi J; Nistala R; Cooper SA; Karuparthi PR; Hayden MR; Rehmer N; DeMarco VG; Andresen BT; Wei Y; Ferrario C; Sowers JR
    Hypertension; 2008 Feb; 51(2):474-80. PubMed ID: 18172055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia.
    Ott C; Ritt M; Titze SI; Schäufele T; Schmieder RE
    J Nephrol; 2009; 22(5):675-81. PubMed ID: 19810001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin II receptor blocker provides pancreatic beta-cell protection independent of blood pressure lowering in diabetic db/db mice.
    Shao JQ; Iwashita N; Du H; Wang YT; Wang YY; Zhao M; Wang J; Watada H; Kawamori R
    Acta Pharmacol Sin; 2007 Feb; 28(2):246-57. PubMed ID: 17241528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
    Cheung RC; Morrell JM; Kallend D; Watkins C; Schuster H
    Int J Cardiol; 2005 Apr; 100(2):309-16. PubMed ID: 15823640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation.
    Solini A; Rossi C; Santini E; Madec S; Salvati A; Ferrannini E
    J Hypertens; 2011 Oct; 29(10):1930-9. PubMed ID: 21881526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy.
    Ii M; Nishimura H; Kusano KF; Qin G; Yoon YS; Wecker A; Asahara T; Losordo DW
    Circulation; 2005 Jul; 112(1):93-102. PubMed ID: 15983249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
    Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC
    Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury.
    Schäfer K; Kaiser K; Konstantinides S
    Thromb Haemost; 2005 Jan; 93(1):145-52. PubMed ID: 15630505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus.
    Schäfer A; Fraccarollo D; Vogt C; Flierl U; Hemberger M; Tas P; Ertl G; Bauersachs J
    Biochem Pharmacol; 2007 May; 73(9):1367-75. PubMed ID: 17270148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.
    Desjardins F; Sekkali B; Verreth W; Pelat M; De Keyzer D; Mertens A; Smith G; Herregods MC; Holvoet P; Balligand JL
    Eur Heart J; 2008 Jan; 29(1):128-37. PubMed ID: 18063594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine.
    Kang BY; Wang W; Palade P; Sharma SG; Mehta JL
    J Cardiovasc Pharmacol; 2009 Oct; 54(4):327-34. PubMed ID: 19687748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statins ameliorate glomerular permeability changes in streptozotocin-induced diabetic rats.
    Mooradian AD; Haas MJ
    Am J Ther; 2007; 14(1):41-5. PubMed ID: 17303974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
    Alter ML; Ott IM; von Websky K; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Klein T; Hocher B
    Kidney Blood Press Res; 2012; 36(1):119-30. PubMed ID: 23171828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    J Atheroscler Thromb; 2011; 18(11):1018-28. PubMed ID: 21921413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1.
    Kang BY; Mehta JL
    J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):283-91. PubMed ID: 19724024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.